China Universal Asset Management Co. Ltd. Buys 3,600 Shares of AstraZeneca Plc $AZN

China Universal Asset Management Co. Ltd. acquired a new stake in shares of AstraZeneca Plc (NYSE:AZN) in the third quarter, Holdings Channel reports. The fund acquired 3,600 shares of the company’s stock, valued at approximately $591,000.

Other institutional investors have also made changes to their positions in the company. Mascoma Wealth Management LLC purchased a new position in AstraZeneca during the 1st quarter worth approximately $26,000. Roxbury Financial LLC purchased a new position in AstraZeneca during the 2nd quarter valued at about $29,000. Resources Management Corp CT ADV purchased a new position in AstraZeneca during the first quarter valued at approximately $35,000. Allied Private Wealth LLC acquired a new stake in AstraZeneca during the second quarter valued at $35,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of AstraZeneca during the 3rd quarter valued at about $30,000. 20.35% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting AstraZeneca

Here are the key news stories impacting AstraZeneca this week:

• Positive Sentiment: Q3 earnings beat expectations: Core EPS reached $2.79 versus the roughly $2.60 analyst consensus, while revenue increased about 7% year over year to $16.21 billion, topping estimates near $16 billion. Net profit rose to $3.12 billion from $2.54 billion a year earlier. AstraZeneca Stock Rallies on Q3 Earnings Beat
• Positive Sentiment: Oncology remains the key growth engine: Cancer-drug sales rose 17%, helping offset generic competition and declining sales from mature medicines such as Farxiga. The performance suggests AstraZeneca’s newer products are mitigating patent-cliff pressure. AZN Q3 Earnings Beat Estimates
• Positive Sentiment: Pipeline catalysts support the longer-term story: Management highlighted more than $20 billion of potential from 2027 drug-trial readouts, while the company reported 12 positive Phase 3 readouts. These catalysts could expand AstraZeneca’s growth prospects beyond its current portfolio. AstraZeneca CEO Sees Over $20B Potential
• Positive Sentiment: Guidance was reaffirmed: AstraZeneca maintained its fiscal 2026 outlook for mid-to-high single-digit revenue growth and low-double-digit core EPS growth at constant exchange rates. The company also targeted $1.5 billion in annual savings, potentially supporting margins and earnings. AstraZeneca Reports Q3 Revenue Growth
• Neutral Sentiment: Analyst views remain mixed: Guggenheim maintained a Buy rating, while Deutsche Bank retained Hold and Erste Group Bank lowered its FY2026 EPS estimate, indicating some valuation and execution concerns remain. Guggenheim Maintains Buy Rating
• Negative Sentiment: Generic competition remains a headwind: Farxiga and other mature products face pricing and volume pressure, which could limit growth if newer oncology and pipeline medicines do not continue to scale. AstraZeneca Holds Guidance

AstraZeneca Price Performance

AZN opened at $186.49 on Friday. The company has a fifty day simple moving average of $164.48 and a 200 day simple moving average of $180.21. AstraZeneca Plc has a 12 month low of $153.41 and a 12 month high of $212.71. The company has a quick ratio of 0.67, a current ratio of 0.89 and a debt-to-equity ratio of 0.47. The stock has a market cap of $289.23 billion, a P/E ratio of 26.38, a P/E/G ratio of 1.45 and a beta of 0.27.

AstraZeneca (NYSE:AZN) last released its quarterly earnings data on Friday, October 30th. The company reported $2.79 EPS for the quarter, beating the consensus estimate of $2.60 by $0.19. The company had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The firm’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.38 EPS. On average, research analysts expect that AstraZeneca Plc will post 10.21 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AZN. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Royal Bank Of Canada started coverage on shares of AstraZeneca in a research report on Tuesday, September 8th. They set an “outperform” rating for the company. Nordea Equity Research raised AstraZeneca from a “sell” rating to a “buy” rating in a research report on Tuesday, October 13th. Zacks Research raised shares of AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Finally, Weiss Ratings upgraded AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday, October 26th. Sixteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $206.67.

AstraZeneca Profile

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.